AC	adriamycin, cyclophosphamide
ALND	axillary lymph node dissection
BCS	breast-conserving surgery
CTx	chemotherapy
CI	confidence interval
CMF	cyclophosphamide, methotrexate, fluorouracil
DFS	disease free survival
DIEP	deep inferior epigastric perforator
EC	epirubicin, cyclophosphamide
ER	endocrine receptor
EQD2	2 Gy equivalent dose
FU	follow-up
HER2	human epidermal growth factor receptor 2
HR	hazard ratio
ICI	immune checkpoint inhibitor
IMN	internal mammary nodes
MTx	mastectomy
naCT	neoadjuvant chemotherapy
naRCT	neoadjuvant radiochemotherapy
naRT	neoadjuvant radiotherapy
naST	neoadjuvant systemic therapy
OS	overall survival
pCR	pathologic complete response
RCB	residual cancer burden
RNI	regional nodal irradiation
RT	radiotherapy
SLND	sentinel lymph node dissection
ST	systemic therapy
TN	triple negative
ypN	postoperative nodal stage
ypT	postoperative primary tumor stage